Evidence map›Paper›PMID 24386271›Full record

ArticlePloS one2013

Fibroblasts derived from human pluripotent stem cells activate angiogenic responses in vitro and in vivo.

Yulia Shamis, Eduardo A Silva, Kyle J Hewitt, Yevgeny Brudno, Shulamit Levenberg, David J Mooney, Jonathan A Garlick

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Vascular biology (Bristol, England) · 2019
    Review
  8. Article
  9. Article
  10. Article
  11. Methodologies in creating skin substitutes.Cellular and molecular life sciences : CMLS · 2016
    Review
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Yulia ShamisProgram in Cell, Molecular and Developmental Biology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, United States of America.
Eduardo A SilvaSchool of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, United States of America ; Wyss Institute For Biological Inspired Engineering, Harvard University, Boston, Massachusetts, United States of America.
Kyle J HewittProgram in Cell, Molecular and Developmental Biology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, United States of America.
Yevgeny BrudnoSchool of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, United States of America ; Wyss Institute For Biological Inspired Engineering, Harvard University, Boston, Massachusetts, United States of America.
Shulamit LevenbergDepartment of Biomedical Engineering, Technion - Israel Institute of Technology, Haifa, Israel.
David J MooneySchool of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, United States of America ; Department of Biomedical Engineering, Technion - Israel Institute of Technology, Haifa, Israel.
Jonathan A GarlickProgram in Cell, Molecular and Developmental Biology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, United States of America.
Tufts University · USHarvard University · USTechnion – Israel Institute of Technology · IL

Funding

Engineering Capillary NetworksR01HL069957 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOONEY, DAVID J · 2003 to 2013
$4.2M
iPSC-derived Repair-Responsive Fibroblasts to Heal Diabetic Foot UlcersR01DK098055 · NIDDK · TUFTS UNIVERSITY BOSTON · PI GARLICK, JONATHAN A · 2012 to 2015
$2.6M
Bioengineered Oral Mucosa from Embryonic Stem Cells for Regenerative MedicineR01DE017413 · NIDCR · TUFTS UNIVERSITY BOSTON · PI GARLICK, JONATHAN A · 2007 to 2011
$2.0M
NHLBI NIH HHS HL069957NHLBI NIH HHS R01 HL069957NIDCR NIH HHS DE017413NIDCR NIH HHS R01 DE017413NIDDK NIH HHS R01 DK098055
6 · The paper itself

Abstract

Human embryonic and induced pluripotent stem cells (hESC/hiPSC) are promising cell sources for the derivation of large numbers of specific cell types for tissue engineering and cell therapy applications. We have describe a directed differentiation protocol that generates fibroblasts from both hESC and hiPSC (EDK/iPDK) that support the repair and regeneration of epithelial tissue in engineered, 3D skin equivalents. In the current study, we analyzed the secretory profiles of EDK and iPDK cells to investigate the production of factors that activate and promote angiogenesis. Analysis of in vitro secretion profiles from EDK and iPDK cells demonstrated the elevated secretion of pro-angiogenic soluble mediators, including VEGF, HGF, IL-8, PDGF-AA, and Ang-1, that stimulated endothelial cell sprouting in a 3D model of angiogenesis in vitro. Phenotypic analysis of EDK and iPDK cells during the course of differentiation from hESCs and iPSCs revealed that both cell types progressively acquired pericyte lineage markers NG2, PDGFRβ, CD105, and CD73 and demonstrated transient induction of pericyte progenitor markers CD31, CD34, and Flk1/VEGFR2. Furthermore, when co-cultured with endothelial cells in 3D fibrin-based constructs, EDK and iPDK cells promoted self-assembly of vascular networks and vascular basement membrane deposition. Finally, transplantation of EDK cells into mice with hindlimb ischemia significantly reduced tissue necrosis and improved blood perfusion, demonstrating the potential of these cells to stimulate angiogenic responses in vivo. These findings demonstrate that stable populations of pericyte-like angiogenic cells can be generated with high efficiency from hESC and hiPSC using a directed differentiation approach. This provides new cell sources and opportunities for vascular tissue engineering and for the development of novel strategies in regenerative medicine.

Indexed as

Cell DifferentiationNeovascularization, PhysiologicAngiogenesis Inducing AgentsAnimalsBiomarkersEmbryonic Stem CellsEndothelial CellsExtremitiesFibroblastsHumansInduced Pluripotent Stem CellsIschemiaMicePericytesPluripotent Stem CellsProteomeAngiogenesis Inducing AgentsBiomarkersProteome

Identifiers

PMID24386271
PMCPMC3875480
OpenAlexW2036353642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.